Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MediWound (MDWD) Capital Expenditures (2016 - 2025)

MediWound has reported Capital Expenditures over the past 13 years, most recently at $8.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 27.1% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $5.5 million, down 12.24%, while the annual FY2025 figure was $5.5 million, 12.24% down from the prior year.
  • Capital Expenditures for Q4 2025 was $8.6 million at MediWound, up from -$1.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $11.7 million in Q4 2024 and troughed at -$3.0 million in Q2 2024.
  • A 5-year average of $915400.0 and a median of -$189000.0 in 2021 define the central range for Capital Expenditures.
  • On a YoY basis, Capital Expenditures climbed as much as 1045.19% in 2023 and fell as far as 1930.12% in 2023.
  • Year by year, Capital Expenditures stood at -$116000.0 in 2021, then skyrocketed by 906.9% to $936000.0 in 2022, then surged by 1045.19% to $10.7 million in 2023, then rose by 9.53% to $11.7 million in 2024, then decreased by 27.1% to $8.6 million in 2025.
  • Business Quant data shows Capital Expenditures for MDWD at $8.6 million in Q4 2025, -$1.0 million in Q3 2025, and -$1.0 million in Q2 2025.